{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:19:06Z","timestamp":1787624346605,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172809"],"award-info":[{"award-number":["82172809"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Fund of Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine","award":["2023DHYGJC-YBA04"],"award-info":[{"award-number":["2023DHYGJC-YBA04"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00210-026-05499-z","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T03:36:57Z","timestamp":1779853017000},"page":"17751-17766","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated experimental and network pharmacology analyses reveal inhibitory effects of albiflorin on renal cell carcinoma cells"],"prefix":"10.1007","volume":"399","author":[{"given":"Kai","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haining","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongrun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"issue":"10","key":"5499_CR1","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1007\/s13346-024-01649-z","volume":"14","author":"T Andreani","year":"2024","unstructured":"Andreani T, Cheng R, Elbadri K, Ferro C, Menezes T, Dos Santos MR, Pereira CM, Santos HA (2024) Natural compounds-based nanomedicines for cancer treatment: future directions and challenges. Drug Deliv Transl Res 14(10):2845\u20132916. https:\/\/doi.org\/10.1007\/s13346-024-01649-z","journal-title":"Drug Deliv Transl Res"},{"key":"5499_CR2","doi-asserted-by":"publisher","unstructured":"Badoiu SC, Greabu M, Miricescu D, Stanescu S II, Ilinca R, Balan DG, Balcangiu-Stroescu AE, Mihai DA, Vacaroiu IA, Stefani C, Jinga V (2023) PI3K\/AKT\/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: crosstalk with the VHL\/HIF Axis. Int J Mol Sci 24(9). https:\/\/doi.org\/10.3390\/ijms24098391","DOI":"10.3390\/ijms24098391"},{"key":"5499_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/srep13470","volume":"5","author":"F Chen","year":"2015","unstructured":"Chen F, Deng J, Liu X, Li W, Zheng J (2015) HCRP-1 regulates cell migration and invasion via EGFR-ERK mediated up-regulation of MMP-2 with prognostic significance in human renal cell carcinoma. Sci Rep 5:13470. https:\/\/doi.org\/10.1038\/srep13470","journal-title":"Sci Rep"},{"issue":"Pt 2","key":"5499_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2025.117563","volume":"243","author":"Z Chen","year":"2026","unstructured":"Chen Z, Zhang Y, Ma L, Song Y, Li W, Sun Z, Chen T, Cheng S, Liu M (2026) Gingerenone A inhibits LDHA-mediated glycolysis and restores sunitinib sensitivity in renal cell carcinoma. Biochem Pharmacol 243(Pt 2):117563. https:\/\/doi.org\/10.1016\/j.bcp.2025.117563","journal-title":"Biochem Pharmacol"},{"key":"5499_CR5","doi-asserted-by":"publisher","unstructured":"Chen Z, Liu M (2025) Natural compounds in cancer therapy: revealing the role of flavonoids in renal cell carcinoma treatment. Biomolecules 15(5). https:\/\/doi.org\/10.3390\/biom15050620","DOI":"10.3390\/biom15050620"},{"key":"5499_CR6","doi-asserted-by":"publisher","unstructured":"Chen Z, Wang C, Cai Y, Xu A, Han C, Tong Y, Cheng S, Liu M (2024) Revealing the mechanism of esculin in treating renal cell carcinoma based on network pharmacology and experimental validation. Biomolecules 14(8). https:\/\/doi.org\/10.3390\/biom14081043","DOI":"10.3390\/biom14081043"},{"issue":"1","key":"5499_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-07403-4","volume":"23","author":"C Dai","year":"2025","unstructured":"Dai C, Hu J, Tian X, Zhou H, Yang Z, Jin S, Zheng J (2025) DCST1-AS1 promotes renal cell carcinoma progression via regulating the miR-582-5p\/HMGB2 axis. J Transl Med 23(1):1352. https:\/\/doi.org\/10.1186\/s12967-025-07403-4","journal-title":"J Transl Med"},{"key":"5499_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.101966","volume":"84","author":"S Fogli","year":"2020","unstructured":"Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, Rini BI, Schmidinger M (2020) Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev 84:101966. https:\/\/doi.org\/10.1016\/j.ctrv.2020.101966","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"5499_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1223-y","volume":"38","author":"D Gong","year":"2019","unstructured":"Gong D, Zhang J, Chen Y, Xu Y, Ma J, Hu G, Huang Y, Zheng J, Zhai W, Xue W (2019) The m(6)A-suppressed P2RX6 activation promotes renal cancer cells migration and invasion through ATP-induced Ca(2+) influx modulating ERK1\/2 phosphorylation and MMP9 signaling pathway. J Exp Clin Cancer Res 38(1):233. https:\/\/doi.org\/10.1186\/s13046-019-1223-y","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"5499_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06526-y","volume":"23","author":"Z Hao","year":"2025","unstructured":"Hao Z, Zhang M, Du Y, Liu J, Zeng G, Li H, Peng X (2025) Invadopodia in cancer metastasis: dynamics, regulation, and targeted therapies. J Transl Med 23(1):548. https:\/\/doi.org\/10.1186\/s12967-025-06526-y","journal-title":"J Transl Med"},{"key":"5499_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113054","volume":"150","author":"S Hashem","year":"2022","unstructured":"Hashem S, Ali TA, Akhtar S, Nisar S, Sageena G, Ali S, Al-Mannai S, Therachiyil L, Mir R, Elfaki I, Mir MM, Jamal F, Masoodi T, Uddin S, Singh M, Haris M, Macha M, Bhat AA (2022) Targeting cancer signaling pathways by natural products: exploring promising anti-cancer agents. Biomed Pharmacother 150:113054. https:\/\/doi.org\/10.1016\/j.biopha.2022.113054","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"5499_CR12","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000506709","volume":"87","author":"W Hou","year":"2020","unstructured":"Hou W, Kaczorowski A, Lantwin P, Kippenberger M, Sch\u00fctz V, Franke D, Dieffenbacher SC, Hohenfellner M, Duensing S (2020) Microenvironment-derived FGF-2 stimulates renal cell carcinoma cell proliferation through modulation of p27Kip1: implications for spatial niche formation and functional intratumoral heterogeneity. Pathobiology 87(2):114\u2013124. https:\/\/doi.org\/10.1159\/000506709","journal-title":"Pathobiology"},{"key":"5499_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107100","volume":"201","author":"L Huang","year":"2024","unstructured":"Huang L, Huang XH, Yang X, Hu JQ, Zhu YZ, Yan PY, Xie Y (2024) Novel nano-drug delivery system for natural products and their application. Pharmacol Res 201:107100. https:\/\/doi.org\/10.1016\/j.phrs.2024.107100","journal-title":"Pharmacol Res"},{"issue":"12","key":"5499_CR14","doi-asserted-by":"publisher","first-page":"8875","DOI":"10.21037\/tcr-2025-1246","volume":"14","author":"T Ji","year":"2025","unstructured":"Ji T, Ye L, Xu C, Ma C, Yin G (2025) Albiflorin enhances the antitumor effects of propofol in hepatocellular carcinoma cells by inhibiting the Wnt\/\u03b2-catenin signaling activation. Transl Cancer Res 14(12):8875\u20138888. https:\/\/doi.org\/10.21037\/tcr-2025-1246","journal-title":"Transl Cancer Res"},{"issue":"6","key":"5499_CR15","doi-asserted-by":"publisher","first-page":"7517","DOI":"10.1007\/s00210-024-03774-5","volume":"398","author":"X Jia","year":"2025","unstructured":"Jia X, Chen Z, Chen X, Zhang H, Sun Z, Wang Z, Liu M (2025) Elucidating the anticancer potential of dendrobine in renal cell carcinoma treatment. Naunyn Schmiedebergs Arch Pharmacol 398(6):7517\u20137528. https:\/\/doi.org\/10.1007\/s00210-024-03774-5","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"5499_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-00909-1","volume":"15","author":"W Jiang","year":"2024","unstructured":"Jiang W, Yuan L, Liu Q, Li X, Yang Y, Li J, Jiao T, Niu Y, Zhang L, Dou H, Nan Y (2024) The mechanism of action and experimental verification of Gan-song Yin on renal clear cell carcinoma based on network pharmacology and bioinformatics. Discover Oncol 15(1):52. https:\/\/doi.org\/10.1007\/s12672-024-00909-1","journal-title":"Discover Oncol"},{"issue":"1","key":"5499_CR17","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbrc.2014.04.064","volume":"448","author":"JH Kim","year":"2014","unstructured":"Kim JH, Lkhagvadorj S, Lee MR, Hwang KH, Chung HC, Jung JH, Cha SK, Eom M (2014) Orai1 and STIM1 are critical for cell migration and proliferation of clear cell renal cell carcinoma. Biochem Biophys Res Commun 448(1):76\u201382. https:\/\/doi.org\/10.1016\/j.bbrc.2014.04.064","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"5499_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1186\/s12967-025-06328-2","volume":"23","author":"Y Li","year":"2025","unstructured":"Li Y, Wang H, Mao D, Che X, Chen Y, Liu Y (2025) Understanding pre-metastatic niche formation: implications for colorectal cancer liver metastasis. J Transl Med 23(1):340. https:\/\/doi.org\/10.1186\/s12967-025-06328-2","journal-title":"J Transl Med"},{"key":"5499_CR19","doi-asserted-by":"publisher","unstructured":"Li M, Cai L, Wang X, Yu Y, Jian W, Bao G, Gao Z, Guo J, Zhang J, Li C, Zhang C (2021) RHBDD1 promotes proliferation, migration, invasion and EMT in renal cell carcinoma via the EGFR\/AKT signaling pathway. Mol Med Rep 24(6). https:\/\/doi.org\/10.3892\/mmr.2021.12466","DOI":"10.3892\/mmr.2021.12466"},{"issue":"1","key":"5499_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101771","volume":"13","author":"C Liu","year":"2026","unstructured":"Liu C, Wang S, Zhang X, Han Y, Tan M, Fan J, Du J, Fan Y, Zhao X (2026) The biomechanical signature of tumor invasion. Genes Dis 13(1):101771. https:\/\/doi.org\/10.1016\/j.gendis.2025.101771","journal-title":"Genes Dis"},{"key":"5499_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2147\/ijn.S443692","volume":"19","author":"Y Lv","year":"2024","unstructured":"Lv Y, Li W, Liao W, Jiang H, Liu Y, Cao J, Lu W, Feng Y (2024) Nano-drug delivery systems based on natural products. Int J Nanomedicine 19:541\u2013569. https:\/\/doi.org\/10.2147\/ijn.S443692","journal-title":"Int J Nanomedicine"},{"key":"5499_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2025.101186","volume":"66","author":"K Ma","year":"2025","unstructured":"Ma K, Li Q, Zhang Y, Wang J, Jia W, Liu J, Liu B, Li Q, Wang Q, Zeng K (2025) CYP1B1 promotes angiogenesis and sunitinib resistance in clear cell renal cell carcinoma via USP5-mediated HIF2\u03b1 deubiquitination. Neoplasia 66:101186. https:\/\/doi.org\/10.1016\/j.neo.2025.101186","journal-title":"Neoplasia"},{"issue":"5","key":"5499_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7010","volume":"13","author":"A Manzari-Tavakoli","year":"2024","unstructured":"Manzari-Tavakoli A, Babajani A, Tavakoli MM, Safaeinejad F, Jafari A (2024) Integrating natural compounds and nanoparticle-based drug delivery systems: a novel strategy for enhanced efficacy and selectivity in cancer therapy. Cancer Med 13(5):e7010. https:\/\/doi.org\/10.1002\/cam4.7010","journal-title":"Cancer Med"},{"key":"5499_CR24","doi-asserted-by":"publisher","unstructured":"Muhammad N, Usmani D, Tarique M, Naz H, Ashraf M, Raliya R, Tabrez S, Zughaibi TA, Alsaieedi A, Hakeem IJ, Suhail M (2022) The role of natural products and their multitargeted approach to treat solid cancer. Cells 11(14). https:\/\/doi.org\/10.3390\/cells11142209","DOI":"10.3390\/cells11142209"},{"issue":"2","key":"5499_CR25","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","volume":"43","author":"C Nogales","year":"2022","unstructured":"Nogales C, Mamdouh ZM, List M, Kiel C, Casas AI, Schmidt H (2022) Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol Sci 43(2):136\u2013150. https:\/\/doi.org\/10.1016\/j.tips.2021.11.004","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"5499_CR26","doi-asserted-by":"publisher","first-page":"716","DOI":"10.4062\/biomolther.2025.020","volume":"33","author":"C Park","year":"2025","unstructured":"Park C, Cha HJ, Kim DG, Hong SH, Moon SK, Jin CY, Kim GY, Kim HS, Lee NY, Shim JH, Choi YH (2025) Albiflorin, a monoterpene glycoside, protects myoblasts against hydrogen peroxide-induced apoptosis by activating the Nrf2\/HO-1 axis. Biomol Ther (Seoul) 33(4):716\u2013727. https:\/\/doi.org\/10.4062\/biomolther.2025.020","journal-title":"Biomol Ther (Seoul)"},{"issue":"5","key":"5499_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/s0959-440x(00)00258-x","volume":"11","author":"L Pellegrini","year":"2001","unstructured":"Pellegrini L (2001) Role of heparan sulfate in fibroblast growth factor signalling: a structural view. Curr Opin Struct Biol 11(5):629\u2013634. https:\/\/doi.org\/10.1016\/s0959-440x(00)00258-x","journal-title":"Curr Opin Struct Biol"},{"issue":"12","key":"5499_CR28","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","volume":"332","author":"TL Rose","year":"2024","unstructured":"Rose TL, Kim WY (2024) Renal cell carcinoma: a review. JAMA 332(12):1001\u20131010. https:\/\/doi.org\/10.1001\/jama.2024.12848","journal-title":"JAMA"},{"issue":"7","key":"5499_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70535","volume":"31","author":"S Sun","year":"2025","unstructured":"Sun S, Hamezah HS, Jin C, Han R, Tong X (2025) Albiflorin on neuropsychiatric and neurodegenerative disorders: a systematic review. CNS Neurosci Ther 31(7):e70535. https:\/\/doi.org\/10.1111\/cns.70535","journal-title":"CNS Neurosci Ther"},{"issue":"5","key":"5499_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101529","volume":"12","author":"S Tian","year":"2025","unstructured":"Tian S, Chen X, Li J (2025) Zinc finger transcription factor ZNF24 inhibits colorectal cancer growth and metastasis by suppressing MMP2 transcription. Genes Dis 12(5):101529. https:\/\/doi.org\/10.1016\/j.gendis.2025.101529","journal-title":"Genes Dis"},{"key":"5499_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110215","volume":"127","author":"J Wang","year":"2020","unstructured":"Wang J, Wang C, Li Q, Guo C, Sun W, Zhao D, Jiang S, Hao L, Tian Y, Liu S, Sun MZ (2020) miR-429-CRKL axis regulates clear cell renal cell carcinoma malignant progression through SOS1\/MEK\/ERK\/MMP2\/MMP9 pathway. Biomed Pharmacother 127:110215. https:\/\/doi.org\/10.1016\/j.biopha.2020.110215","journal-title":"Biomed Pharmacother"},{"key":"5499_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1582887","volume":"16","author":"B Wang","year":"2025","unstructured":"Wang B, Xiang Y, Liu X, Pan X, Peng L, Ma J (2025a) Advances in immunotherapy and targeted therapy for advanced clear-cell renal cell carcinoma: current strategies and future directions. Front Immunol 16:1582887. https:\/\/doi.org\/10.3389\/fimmu.2025.1582887","journal-title":"Front Immunol"},{"issue":"1","key":"5499_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41420-025-02385-0","volume":"11","author":"F Wang","year":"2025","unstructured":"Wang F, Li L, Sun X, Cai X, Wang J, Luo H, Wang Y, Ni D, Wang D (2025b) The feedback loop between miR-222-3p and ZEB1 harnesses metastasis in renal cell carcinoma. Cell Death Discov 11(1):97. https:\/\/doi.org\/10.1038\/s41420-025-02385-0","journal-title":"Cell Death Discov"},{"issue":"1","key":"5499_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02766-5","volume":"11","author":"J Wang","year":"2025","unstructured":"Wang J, Luo H, He Q, Shao H, Cai X, Cao Y, Wang Y, Wang D (2025c) NCOA7 inhibits renal cancer progression by inducing autophagy and lipid metabolism through V-ATPase interaction. Cell Death Discov 11(1):471. https:\/\/doi.org\/10.1038\/s41420-025-02766-5","journal-title":"Cell Death Discov"},{"issue":"1","key":"5499_CR35","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1186\/s12967-025-06596-y","volume":"23","author":"Q Wang","year":"2025","unstructured":"Wang Q, Feng W, Tan Y, Qiao J, Liu H, Liu Q, Wang H, Zhang Q, Tao J, Li Z, Yang B, Xu Z, Wang C, Yang S, Cui L (2025d) Antiphospholipid antibodies inhibit the migration and invasion of trophoblast cells by suppressing the JNK\/C-Jun\/MMP1 signaling pathway. J Transl Med 23(1):581. https:\/\/doi.org\/10.1186\/s12967-025-06596-y","journal-title":"J Transl Med"},{"issue":"1","key":"5499_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02536-3","volume":"11","author":"Z Wang","year":"2025","unstructured":"Wang Z, Sun H, Zhu S, Wang F, Li Q, Zhou J (2025e) RGS3 acts as a tumor promoter by facilitating the regulation of the TGF-\u03b2 signaling pathway and promoting EMT in ovarian cancer. Cell Death Discov 11(1):262. https:\/\/doi.org\/10.1038\/s41420-025-02536-3","journal-title":"Cell Death Discov"},{"issue":"4","key":"5499_CR37","doi-asserted-by":"publisher","first-page":"tfaf105","DOI":"10.1093\/toxres\/tfaf105","volume":"14","author":"L Xie","year":"2025","unstructured":"Xie L, Wang Y, Gong Y (2025) Albiflorin improves diabetic retinopathy by mitigating oxidative stress and inflammation via the TLR-4\/NF-kB signaling pathway. Toxicol Res (Camb) 14(4):tfaf105. https:\/\/doi.org\/10.1093\/toxres\/tfaf105","journal-title":"Toxicol Res (Camb)"},{"issue":"2","key":"5499_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2025.101688","volume":"13","author":"W Xie","year":"2026","unstructured":"Xie W, Fu Z, Skutella T, Jiang Q, Zhang R, Zhang Y (2026) CTHRC1 promotes the progression of clear cell renal cell carcinoma via the PI3K\/AKT\/GSK3\u03b2 signaling pathway. Genes Dis 13(2):101688. https:\/\/doi.org\/10.1016\/j.gendis.2025.101688","journal-title":"Genes Dis"},{"issue":"1","key":"5499_CR39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41420-024-01962-z","volume":"10","author":"P Xing","year":"2024","unstructured":"Xing P, Liu H, Xiao W, Zhang G, Zhang C, Liao Z, Li T, Yang J (2024) The fusion gene LRP1-SNRNP25 drives invasion and migration by activating the pJNK\/37LRP\/MMP2 signaling pathway in osteosarcoma. Cell Death Discov 10(1):198. https:\/\/doi.org\/10.1038\/s41420-024-01962-z","journal-title":"Cell Death Discov"},{"issue":"1","key":"5499_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12967-023-03913-1","volume":"21","author":"J Xu","year":"2023","unstructured":"Xu J, Wang Y, Jiang J, Yin C, Shi B (2023) ADAM12 promotes clear cell renal cell carcinoma progression and triggers EMT via EGFR\/ERK signaling pathway. J Transl Med 21(1):56. https:\/\/doi.org\/10.1186\/s12967-023-03913-1","journal-title":"J Transl Med"},{"issue":"1","key":"5499_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02503-y","volume":"11","author":"DM Xu","year":"2025","unstructured":"Xu DM, Chen LX, Xue T, Zhuang XY, Wei LC, Han H, Mo M (2025) Decoding the impact of MMP1+ malignant subsets on tumor-immune interactions: insights from single-cell and spatial transcriptomics. Cell Death Discov 11(1):244. https:\/\/doi.org\/10.1038\/s41420-025-02503-y","journal-title":"Cell Death Discov"},{"issue":"1","key":"5499_CR42","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41420-025-02848-4","volume":"12","author":"W Yang","year":"2026","unstructured":"Yang W, Li Y, Li Z, Jiang C, Deng X, Peng D (2026) HSP90AA1 restrains clear cell renal cell carcinoma progression by promoting CADM1 expression and suppressing the PI3K-AKT pathway through interaction with FBXO7. Cell Death Discov 12(1):6. https:\/\/doi.org\/10.1038\/s41420-025-02848-4","journal-title":"Cell Death Discov"},{"key":"5499_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.biopha.2018.07.054","volume":"107","author":"H Zhang","year":"2018","unstructured":"Zhang H, Ye Q, Du Z, Huang M, Zhang M, Tan H (2018) MiR-148b-3p inhibits renal carcinoma cell growth and pro-angiogenic phenotype of endothelial cell potentially by modulating FGF2. Biomed Pharmacother 107:359\u2013367. https:\/\/doi.org\/10.1016\/j.biopha.2018.07.054","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"5499_CR44","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s10753-024-01978-8","volume":"47","author":"L Zhang","year":"2024","unstructured":"Zhang L, Xu J, Yin S, Wang Q, Jia Z, Wen T (2024a) Albiflorin attenuates neuroinflammation and improves functional recovery after spinal cord injury through regulating LSD1-mediated microglial activation and ferroptosis. Inflammation 47(4):1313\u20131327. https:\/\/doi.org\/10.1007\/s10753-024-01978-8","journal-title":"Inflammation"},{"issue":"9","key":"5499_CR45","doi-asserted-by":"publisher","first-page":"4774","DOI":"10.1002\/ptr.8295","volume":"38","author":"ZH Zhang","year":"2024","unstructured":"Zhang ZH, Yuan CY, Xu M, Wang MF, Feng T, Wang Y, Zheng SF, Zhang HL, Shi GH, Cao DL, Wang ZL, Ye DW (2024b) Calycosin inhibits the proliferation and metastasis of renal cell carcinoma through the MAZ\/HAS2 signaling pathway. Phytother Res 38(9):4774\u20134791. https:\/\/doi.org\/10.1002\/ptr.8295","journal-title":"Phytother Res"},{"issue":"1","key":"5499_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-025-02479-9","volume":"11","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Zhang S, Sun H, Xu L (2025) The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma. Cell Death Discov 11(1):186. https:\/\/doi.org\/10.1038\/s41420-025-02479-9","journal-title":"Cell Death Discov"},{"issue":"1\u20132","key":"5499_CR47","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000546879","volume":"49","author":"XW Zhang","year":"2026","unstructured":"Zhang XW, J\u00e4ger D, Zsch\u00e4bitz S (2026) Management of advanced renal cell carcinoma. Oncol Res Treat 49(1\u20132):26\u201334. https:\/\/doi.org\/10.1159\/000546879","journal-title":"Oncol Res Treat"},{"key":"5499_CR48","doi-asserted-by":"publisher","unstructured":"Zhang P, Zhang D, Zhou W, Wang L, Wang B, Zhang T, Li S (2023) Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. Brief Bioinform 25(1). https:\/\/doi.org\/10.1093\/bib\/bbad518","DOI":"10.1093\/bib\/bbad518"},{"key":"5499_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176840","volume":"980","author":"X Zheng","year":"2024","unstructured":"Zheng X, Wang Y, Qiu X (2024) Comprehensive analysis of MAPK genes in the prognosis, immune characteristics, and drug treatment of renal clear cell carcinoma using bioinformatic analysis and Mendelian randomization. Eur J Pharmacol 980:176840. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176840","journal-title":"Eur J Pharmacol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05499-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05499-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T01:23:29Z","timestamp":1787621009000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05499-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["5499"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05499-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"14 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}